Signaling Control by Epidermal Growth Factor Receptor and MET: Rationale for Cotargeting Strategies in Lung Cancer
- 10 November 2013
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (32) , 4148-4150
Abstract
See accompanying article doi: 10.1200/JCO.2013.50.8234 Author affiliations appear at the end of this article. Published online ahead of print at www.jco.org on October 7, 2013Keywords
This publication has 43 references indexed in Scilit:
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET AmplificationJournal of Thoracic Oncology, 2011
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to PaclitaxelCancer Research, 2008
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 2008
- Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to GeldanamycinsCancer Research, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Specificity in Signal TransductionCell, 2004